Uses / Indications: PRIMARY INDICATION: Type 2 Diabetes Mellitus (T2DM) in adults: as adjunct to diet and exercise to improve glycaemic control Monotherapy: when metformin is not tolerated or is contraindicated Add-on therapy: in combination with other oral antidiabetics (metformin, SGLT2 inhibitors, sulfonylureas, thiazolidinediones) or basal insulin when existing therapy does not provide adequate blood glucose control DOSE-SPECIFIC ROLE OF RYBELSUS 3MG: Rybelsus 3mg is the INITIATION DOSE ONLY used for the first 30 days to improve gastrointestinal tolerability It is NOT a therapeutic (blood-sugar lowering) dose clinical trials demonstrated minimal HbA1c lowering at 3mg After 30 days: step up to Rybelsus 7mg once daily (therapeutic dose) After a further 30 days at 7mg: if additional control needed, step up to Rybelsus 14mg once daily (maximum dose) ADDITIONAL INVESTIGATIONAL / OFF-LABEL CONTEXT: Cardiovascular risk reduction: injectable semaglutide (Ozempic) has established CV benefit in T2DM with CVD
Data were log 10 transformed if they were non-normally distributed and/or heteroscedastic
Like protein and fibre, healthy fats slow transit time as food leaves the stomach
Sleep Disturbance and Gastrointestinal Symptom Sensitivity: BrainGut Axis Mechanisms
Payers are fronting high acquisition costs for these biologics, but the value proposition evaporates if the patient drops off before reaching the maintenance phase
[199] Raymond LJ, Ralston NVC
